DEINOVE – Update on the Receivership Proceedings

By Dr. Matthew Watson

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court has met on December 16, 2022, and postponed the examination of the case to January 13, 2023. The continuation of the observation period (“période d'observation”) was requested by the bodies of the proceedings and the company DEINOVE.

Read more:
DEINOVE - Update on the Receivership Proceedings

Related Post


categoriaGlobal News Feed commentoComments Off on DEINOVE – Update on the Receivership Proceedings | dataDecember 17th, 2022

About...

This author published 5852 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024